Darwin Global Management, Ltd. Fate Therapeutics Inc Transaction History

Darwin Global Management, Ltd.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $4.56 Million - $9.26 Million	-153,537 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $9.55 Million - $12.8 Million	-199,713 Reduced 56.54%	153,537 $8.98 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $1.03 Million - $1.66 Million	17,332 Added 5.16%	353,250 $20.9 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $69.6 Million - $95.7 Million	-1,034,215 Reduced 75.48%	335,918 $29.2 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $30.1 Million - $49 Million	417,286 Added 43.79%	1,370,133 $113 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $36.3 Million - $96.2 Million	952,847 New	952,847 $86.6 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Darwin Global Management, Ltd., based on Form 13F filings with the SEC.

Stay updated on Darwin Global Management, Ltd. with notifications on news.